Pfizer announced that its antibody‑drug conjugate Elrexfio met the primary endpoint of progression‑free survival (PFS) in the MagnetisMM‑5 phase 3 trial for patients with relapsed or refractory multiple myeloma who had received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.
The MagnetisMM‑5 study enrolled 497 adults across 26 countries and compared Elrexfio monotherapy to daratumumab plus pomalidomide and dexamethasone (DPd). Progression‑free survival was assessed by blinded independent central review, and the trial demonstrated a statistically significant and clinically meaningful improvement in PFS for the Elrexfio arm.
Safety data from the trial were consistent with earlier studies, with no new safety signals identified. The drug’s safety profile aligns with its accelerated‑approval status, which was granted in 2023 for patients who had received at least four prior lines of therapy and a conditional marketing authorization in the EU.
Elrexfio generated $74 million in global sales in 2025, a 30% increase from 2024, yet it has yet to gain meaningful commercial momentum. The positive MagnetisMM‑5 results will be discussed with global health authorities and could support earlier‑line approvals, expanding the drug’s addressable market and potentially boosting future sales.
The trial’s success reinforces Pfizer’s strategy to expand its oncology portfolio, particularly its ADC and bispecific antibody programs that were accelerated by the Seagen acquisition. By demonstrating efficacy in a double‑class‑exposed population, Elrexfio strengthens Pfizer’s competitive position against established therapies such as Darzalex, Tecvayli, and Regeneron’s Lynozyfic, and positions the company for broader regulatory submissions and market penetration.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.